There are only limited data in patients with liver impairment and on the effects of medicinal products known to influence hepatic metabolism (e. g. cimetidine).
Maksakahjustusega patsientidel kasutamise ja ravimi metaboliseerumist maksas mõjutavate ravimite (nt tsimetidiini) toimete kohta on vähe andmeid.